 BeyondSpring Inc. the Company or BeyondSpring BYSI, a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced the pricing of its public offering of 1,930,000 ordinary shares at a public offering price of 13.00 per share. The Company also announced the sale of an aggregate of 384,615 ordinary shares at the public offering price to entities affiliated with Decheng Capital in a separate private placement transaction. 